Ex Vivo Cell &
Providing the engineering expertise to
optimize therapies for patients.
Ex Vivo Cell & Gene Therapies
Autologous Cell Therapy
Autologous cell therapy is a form of personalized medicine that uses a patient’s own genetically modified immune cells to treat disease. In autologous therapies, cells are removed from a patient, engineered to elicit the desired therapeutic effect, and reintroduced to the patient.
To create autologous therapies, like chimeric antigen receptor (CAR) T and T cell receptor (TCR) cell therapies, ElevateBio combines target selection, cell and vector engineering and gene editing to modify cells and optimize their performance.
Powering Cell and Gene Therapies with Our Technology Platforms
With proprietary gene editing, iPSCs, and cell, protein, and vector engineering technologies and the ability to combine them, we can power the entire cell and gene therapy industry.
We help our partners scale new heights in cell and gene therapies by providing a full spectrum of viral vector and cell therapy capabilities to bring concepts to commercialization.
Partner with ElevateBio®
Wherever you are in your cell and gene therapy product lifecycle, we can strengthen and accelerate the development of your transformative therapies with our enabling technologies unmatched manufacturing capabilities.
// Work with us